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A B S T R A C T
The ovarian hyperstimulation syndrome (OHSS) is typically an iatrogenic complication of induction ovulation occur-
ring during the luteal phase or early pregnancy. However, the spontaneous form of OHSS is extremely rare and always
reported during pregnancy. Several cases have been observed during multiple pregnancies and other cases were associ-
ated with hypothyroidisem. Moreover, a few mutations of the follicle-stimulation hormone receptor (FSHr) were recently
described in spontaneous OHSS and normal levels of human chorionic gonadotrophin (HCG). In these cases, a molecu-
lar basis for the pathogenesis of the spontaneous OHSS was identified. These mutations displayed promiscuous sensitiv-
ity and activation by both HCG and thyroid stimulating hormone (TSH). The disease always occurs in the presence of ei-
ther exogenous or endogenous HCG which is thought to play a crucial role in the develpoment of OHSS. The hallmark of
OHSS is an increase in capillary permeability resulting in a fluid shift from the intravascular compartment into the
third space. It is assumed that HCG induces the release of certain ovarian vasoactive substances or mediators that have
potent and direct systemic effects on the vascular system. It was demonstrated that the endothelium, along with the ovary
is a primary target for HCG. Of all the different vasoactive components, vascular endothelial growth factor (VEGF) is the
principal mediator and the most responsible for increased capillary permeability. It is produced and secreted in the ovary
or in the endothelium, and acts through the VEGF receptor-2 or high affinity receptors (KDR and flt 1), respectively. In
addition to VEGF, HCG may trigger activation of the renin-angiotensin system and kinin-kallikrein system together
with releasing of interleukins (6,18), endothelial-cell adhesion molecules, von Willebrand factor, angiogenin and endo-
thelin-1, that also increase vascular permeability.
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Introduction
Ovarian hyperstimulation syndrome (OHSS) is al-
most in all cases an iatrogenic, and potentially life-
-threatening complication of ovarian stimulation. It is
typically associated with the use of exogenous gonado-
trophins and aggressive controlled ovarian hyperstimu-
lation or occasionally with clomiphene citrate, occurring
during the luteal phase or early pregnancy. However,
some forms of OHSS always reported during pregnancy
may be associated extremely rarely with a spontaneous
ovulatory cycle, usually in the case of multiple gesta-
tions, hydatid mole, hypothyreoidism, polycystic ovary
syndrome (PCOS), and follicle-stimulating hormone re-
ceptor (FSHr) mutations1,2. Spontaneous forms of OHSS
are generally reported to develop between 8 and 14
weeks amenorrhoea, differing from iatrogenic OHSS
usually starting between 3 and 5 weeks amenorrhoea.
In the initial form of OHSS, the increase in size of the
ovaries is accompanied by abdominal discomfort. In a
more advanced form, the ovaries become cystic and this
will often result in abdominal distension and pain, nau-
sea, vomiting and sometimes diarrhoea. Severe forms are
characterized by a massive ovarian enlargement with the
formation of multiple ovarian cysts associated with ex-
travascular fluid shifts resulting in the development of
ascites. This extravascular protein-rich exudate accumu-
lates in the peritoneum, in the pleura, and even in the
pericardiac space and is associated with intravascular
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volume depletion and haemoconcentration, hypoalbumi-
naemia, liver dysfunction, hypovolaemia, oliguria, elec-
trolyte imbalance and thromboembolic phenomena. The
manifestations of OHSS are believed to result from an
increased capillary permeability of mesothelial surfaces
under the action of one or several vasoactive factors,
which leads to a loss of protein-rich fluid from the intra-
vascular compartment into the third space3. Risk factors
for developing OHSS include age <35 years, low body
mass index, higher absolute or rapidly rising serum
estradiol levels, PCOS, higher doses of exogenous gona-
dotrophins, and previous episodes of OHSS4.
Since the 1960s, OHSS has been repeatedly reclassi-
fied and in some case, up to six grades of severity have
been distinguished. A real effort to achieve a consensus
on the modern classification of OHSS by a panel of ex-
perts should be made, in a manner similar to the consen-
sus that had been reached by the professional societies
on the definition of polycystic ovarian syndrome (The-
saloniki ESHRE/ASRM-Sponsored Consensus Workshop
Group 2008)5. The overall incidence of OHSS is esti-
mated at 0.6–14%, with 1–10% of cases being classified as
mild to moderate and 0.2–5% as severe. The World Heal-
th Organisation (WHO) has calculated the world-wide in-
cidence of severe OHSS as 0.2–1% of all cycles occurring
in assisted reproduction. The mortality rate is estimated
as one in 45,000 to one in 50,0006. Although the preva-
lence of the severe form of OHSS is small (0.2–5%) never-
theless, as this is an iatrogenic complication of a non-vi-
tal treatment with a potential fatally outcome, the syn-
drome remains a serious problem for specialists dealing
with infertility.
The pathogenesis of OHSS is a complex process and
still unclear. It is assumed that certain ovarian bio-
synthetic components produced in excess during induc-
tion of ovulation initiate the cascade of events that result
in the syndrome. Human chorionic gonadotrophin (HCG)
either exogenous or endogenous (e.g. pregnancy derived)
is the factor which triggers OHSS and seems to be the
pivotal stimulus of the syndrome in a susceptible woman,
because elimination of HCG will prevent the full-blown
picture of the syndrome1,2. Early OHSS is an acute con-
sequence of the exogenous HCG administration before
oocyte retrieval and is usually related to an excessive
ovarian response to gonadotrophin stimulation. It is no-
teworthy that the kinetics of the symptoms are closely
related to the lifespan of the corpus luteum. During iat-
rogenic OHSS, in the absence of pregnancy, the symp-
toms and complications will resolve spontaneously with
the onset of the menses. Late OHSS is induced by endog-
enous HCG from the initiated pregnancy and is observed
only in the patients who become pregnant, especially in
those with more than one gestational sac, and is more
likely to be severe. However, late OHSS is reported as be-
ing able to complicate a non-conception cycle also follow-
ing additional administration of HCG during the luteal
phase. OHSS with onset >10 days after oocyte retrieval
is classified as »late« OHSS and the earlier onset as
»early« OHSS. Although late onset OHSS is strongly as-
sociated with pregnancy, a surprisingly high initial preg-
nancy rate was observed even in early OHSS (50% per
embryo transfer) and a higher risk of preclinical miscar-
riage rate (31.8%)7.
The pathophysiology of spontaneous OHSS has not
yet been eluciated. In certain circumstances – for exam-
ple, in multiple pregnancy, hydatid mole or PCOS – it is
theoretically possible that there could be a greater likeli-
hood of OHSS, since HCG values may be raised above the
normal level. However, even within these entities the
prevalence of OHSS is very low because only several
cases have been observed. This could be taken as an indi-
cator that HCG is a major – but not the only – triggering
mechanism in OHSS8. Moreover, after exclusion the ca-
ses with gestational trophoblastic disease, multiple preg-
nancies and iatrogenic OHSS, none of the patients with
elevated HCG experienced OHSS. It was suggested that
elevated HCG cannot be responsible for OHSS as a single
factor and a combination of mechanisms may allow un-
derstanding of this enigmatic disorder9. Other cases of
spontaneous OHSS were associated with hypothyreoi-
dism and it was suggested that the high levels of thy-
roid-stimulating hormone (TSH) could stimulate the
ovaries10. On the other hand, there have been several re-
ports of familial or habitual spontaneous cases of severe
OHSS. In these cases, a molecular basis for the pa-
thophysiology of the spontaneus OHSS was identified for
the first time because molecular–genetic evidence of a de-
fect in the FSHr was found2. The recent identification of
mutations in the FSHr gene in several patients shows
that mutations may have a role in certain forms of
OHSS. The FSHr mutation appears to cause a reduction
in ligand specifity, which allows activation of the mutated
receptor by HCG. When tested in vitro, the functional re-
sponse of the mutant receptor displayed an enhanced
basal activity and an increased sensitivity to HCG. The
abnormal functionality of mutant FSH receptors in vitro
provides a straightfoward explanation for their implica-
tion in the OHSS development in vivo. The mutated
FSHr expressed in the developing follicles, abnormally
sensitive to HCG, may be hyperstimulated by the preg-
nancy-derived HCG. Accordingly, the follicles may start
growing, enlarge and finally acquire luteinizing hormone
(LH) receptors on granulosa cells which may also be
stimuated by HCG, inducing massive follicular lutei-
nization together with the secretion of vasoactive media-
tors responsible for the development of the syndrome.
The interaction between HCG and FSHr could be an es-
sential prerequisite in the development of spontaneous
OHSS and could explain why symptoms in spontaneous
cases of OHSS appear later than in iatrogenic. Moreover,
high levels of thyroid-stimulating hormone (TSH) might
be also capable of stimulating a mutated FSHr in the
same way as HCG with hypothyroidism10,11. In addition
to five different activating FSHr gene polymorphisms
which were recently described, Asp567Asn, Asp567Gly,
Thr449Ile, Thr449Ala, Ile445Thr, a new mutation,
Ile445Thr, was found in a patient with spontaneous
OHSS of the first trimester of pregnancy with a normal
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HCG level. When tested functionally, this mutant dis-
played promiscuous activation by both HCG and TSH to-
gether with detactable constitutive activitiy. In constra-
st, no mutations were found in the FSHr patients with
high HCG or TSH levels, indicating that for those pa-
tients, spontaneous OHSS results from the natural pro-
miscuous stimulation of a wild-type FSHr by very high
concetrations of HCG or TSH12. This molecular basis for
the pathophysiology of spontaneous OHSS opens up new
perspectives for a better understanding of the way in
which iatrogenic OHSS develops. While a mutation in
the FSHr gene should be sought in patients with habit-
ual or familial OHSS, it would be interesting in iatro-
genic cases of severe hyperstimulation to search poly-
morphisms in the hormone receptor genes or glycoprotein
hormone genes. However, it was found that the FSHr ge-
notype did not play a significant role because of the ab-
sence of FSHr activating mutations in women with iatro-
genic OHSS13.
Recent investigations have focused on various va-
soactive substances and mediators, because it is clear
that profound alterations in the vascular compartment
are the major initial changes that lead to the full appea-
rence and maintenance of OHSS. Thus, either exogenous
or endogenous HCG may induce the release of mediator
that has potent and direct systemic effects on the vascu-
lar system and that may be responsible for the patho-
physiology and clinical consequences. Among the many
candidates that may mediate the action of HCG on the
vascular tree, there are few that are highly involved in
the pathogenesis of the syndrome: vascular endothelial
growth factor (VEGF), other cytokines (interleukins 1, 2,
6, 8, 10, 18 and tumor necrosis factor-alfa), estradiol,
prostaglandins, ovarian-renin angiotensin system, insu-
lin-like growth factor 1, epidermal growth factor, trans-
forming growth factors, von Willebrand factor, endothe-
lial adhesion molecules, angiogenin, endothelin-1, ovarian
kinin-kalikrein system and histamines1,14.
Of all the different candidates, VEGF, also known as
vascular permeability factor, has been proposed as the
main cytokine involved in the pathophysiology of OHSS.
Current findings suggest that this heparin-binding di-
meric polypeptid, with a moleular weight of 40–46 kDa,
is the principal mediator and the most responsible for in-
creased capillary permeability leading to extravasation of
protein-rich fluid and subsequently OHSS. It has been
shown that VEGF increase dramatically after HCG stim-
ulation suggesting a role for HCG hormone regulation of
VEGF production and secretion in luteinized granulosa
cells15. Using an in-vivo murine model to induce OHSS it
was clearly demonstrated that VEGF is produced, ex-
pressed and secreted in the ovary and that it acts thro-
ugh the VEGF receptor-2 to increase vascular permeabil-
ity in response to HCG. The reversal of the increased
vascular permeability using a synthetic VEGF receptor-2
inhibitor (SU5416) provides new insights into the pre-
vention of OHSS16. Another potential source and target
for vasoactive substances is the endothelium because
high-affinity VEGF receptors (KDR and flt1) are located
almost exclusively in the vascular endothelia. It was
demonstrated that the endothelium, along with the ova-
ry, is a primary target for HCG. As a result, VEGF and its
KDR receptors are stimulated, resulting in an accute re-
lease of VEGF and increased capillary permeability in re-
sponse to HCG. Blocking VEGF action with specific anti-
bodies prevents the changes induced by HCG such as
modifications in the actin fibers indicative of increased
capillary permeability observed by confocal microscopy17.
Permeability assays demonstrated that vascular endo-
thelial cadherin, an interendothelial adhesion molecule,
may play a role in the development and progression of se-
vere capillary permeability in severe OHSS. HCG and
VEGF produce a significant increase in vascular endo-
thelial cadherine release, which is involved in the loosen-
ing of endothelial intercellular junctions18,19. A novel para-
digm suggests that HCG can increase endothelial perme-
ability by up-regulating VEGF in co-cultures of luteini-
zed granulosa cells, by altering expression of the endo-
thelial cell-specific adhesion protein claudin-520. It is a
clinical observation that not all women with a high re-
sponse develop OHSS and absolute values of serum VEGF
seem useless in predicting which woman will develope
OHSS21. This individual variability was related to signifi-
cantly higher level of alfa2-macroglobulin, that binds
VEGF to a greater degree than occurs in patients who de-
velop OHSS. Patients who had a raised alfa2-macro-
globulin value in the stimulation phase developed OHSS
less frequently. Interestingly, a major serum protein,
alfa2-macroglobulin, plays an important role as an an-
tagonist to VEGF and influencing the severity of OHSS,
suggesting that it may act by removing and inactivating
free VEGF22.
In addition to VEGF as the principal mediator by
which HCG might increase capillary permeability in
OHSS, other cytokines – particullary interleukins 1, 2, 6,
8, 10, 18 and tumor necrosis factor-alfa – appear to be in-
volved in the aggravation of OHSS. Significantly higher
levels have been observed particularly in ascites and se-
rum from OHSS patients. A statistically significant cor-
relation between serum interleukins (6, 18) and capillary
hyperpermeability was recorded, suggesting a possible
role in the pathophysiology of severe OHSS23,24. Because
estrogen levels are greatly elevated in OHSS patients, it
was postulated that the increase in its production causes
the increase in capillary permeability. If the values are
over 3000–3500 pg/mL at the time of HCG injection, the
risk of developing OHSS is high. However, its reliability
has been questioned especially since OHSS also occurs in
patients who conceive spontaneously and whose pre-
-ovulatory estradiol levels are far less than those encoun-
tered after pharmacological ovarian stimulation. There-
fore, most research groups consider that estradiol is not
an active mediator of OHSS, but rather that high serum
values make it a marker hormone for patients who are at
risk25. Patients with PCOS who have a tendency towards
OHSS usually have insulin resistence and increased in-
sulin levels. Although insulin can stimulate the release of
VEGF in the corpus luteum, serum insulin levels do not
M. Kasum: Development of Ovarian Hyperstimulation Syndrome, Coll. Antropol. 34 (2010) 3: 1139–1143
1141
appear raised in OHSS patients26. In patients with
OHSS, there is a marked increase in the serum levels of
plasma renin, norepinephrine, vasopressin, and atrial
natriuretic peptide. In early-onset OHSS, HCG may trig-
ger activation of the renin-angiotensin system in addi-
tion to the release of VEGF and other mediators. Go-
nadotrophins, as well as HCG, increase production of the
renin from prorenin in luteinized thecal cells and its ac-
tivity in the follicle and in peritoneal fluid. Activation of
the renin-angiotensin system is apparently a causative
pathological mechanism in the development of OHSS27.
There also appears that activation of the kinin-kallikrein
system enhances capillary permeability and vasodila-
tation in OHSS patients28. Three of the best examined
endothelial-cell adhesion molecules (E-selectin, vascular
cell adhesion molecule-1 and intercellular adhesion mol-
ecule-1), were shown to be elevated in ascitic fluid and se-
rum of patients with severe OHSS. The exaggerated
leukcyte recruitment and transendothelial migration de-
scribed in OHSS may cause leukocyte-mediated tissue
damage and capillary hyperpermeability, linking these
molecules in the pathogenesis of the syndrome29. In se-
vere cases of OHSS prior to clinical manifestations, von
Willebrand factor, a large adhesive glycoprotein, is also
released in excess amounts by endothelial lesions. This
could be helpful in planning early, prophylactic treat-
ment of the syndrome30. The polypeptide angiogenin was
shown to be increased 40-fold in serum and 10-fold in
ascitic fluid in women with OHSS compared with women
undergoing ovulation induction who did not suffer from
OHSS. Thus, angiogenin may play a role in the process of
increased vascular permeability in patients wih OHSS31.
The endothelial derived peptide known as endothelin-1 is
a potent vasoconstrictor that also increases vascular per-
meability with other vasoactive factors32. The role of
prostaglandins and histamine is secondary to other fac-
tors and there is no evidence for their primary role in the
pathogenesis of OHSS1,2.
In conclusion, several recent findings of FSHr muta-
tions which allow activation of the mutated receptor by
HCG in patients with spontaneous OHSS and normal
levels of HCG, provide the molecular basis for the patho-
genesis of the syndrome. Either exogenous or endoge-
nous HCG is thought to play a crucial role in the develop-
ment of OHSS. It is assumed that HCG induces the
release of certain ovarian byosythetic components or me-
diators that are thought to be responsible for the in-
creased capillary permeability. Of all the different vaso-
active substances, VEGF has been proposed as the main
cytokine in the pathophysiology of OHSS, in addition to
interleukins, ovarian renin-angiotesin system, kinin-ka-
llikrein system, von Willebrand factor, endothelial-cell
adhesion molecules, angiogenin and endothelin-1.
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NOVI UVIDI U MEHANIZMIMA NASTANKA OVARIJSKOG HIPERSTIMULACIJSKOG SINDROMA
S A @ E T A K
Ovarijski hiperstimulacijski sindrom (OHS) je tipi~na jatrogena komplikacija indukcije ovulacije koja se javlja u
luteinskoj fazi ciklusa ili u ranoj trudno}i. No, spontani oblik OHS je iznimno rijedak i javlja se uvijek u trudno}i.
Nekoliko ih je slu~ajeva opa`eno za vrijeme vi{estrukih trudno}a, dok su drugi slu~ajevi bili povezani s hipotireozom.
Pored toga, nedavno je kod spontanog OHS s normalnim razinama humanog korionskog gonadotropina (HCG) opisano
nekoliko mutacija folikularno stimuliraju}eg hormona (FSH). U tim slu~ajevima prepoznata je molekularna osnova u
nastanku spontanog OHS. Takve mutacije odra`avaju mije{anu osjetljivost i aktivnost prema HCG i prema tireoidnom
stimuliraju}em hormonu (TSH). OHS se javlja uvijek nazo~nosti egzogenog ili endogenog HCG za kojeg se smatra da
igra glavnu ulogu u razvijanju bolesti. Poja~ana kapilarna propusnost je obilje`je OHS koje rezultira pomakom teku}ine
iz intravaskularnog prostora u odjeljak tre}eg prostora. Smatra se da HCG inducira otpu{tanje vazoaktivnih tvari ili
medijatora, koje imaju sna`ne i izravne u~inke na krvo`ilni sustav. Pokazano je da su endometrij kao i jajnik primarna
ciljna mjesta na koja djeluje HCG. Od svih raznovrsnih vazoaktivnih tvari, vaskularni endotelni faktor rasta (VEFR) je
glavni medijator i najodgovorniji za poja~anu kapilarnu propusnost. On nastaje i lu~i se u jajniku i endotelu, a djeluje
preko svojih receptora tipa-2 odnosno KDR i flt 1. Osim poticanja VEGF, HCG mo`e aktivirati sustave renin-angio-
tenzina i kinin-kalikreina sustav, a isto tako otpu{ta interleukine (6,18), adhezivne molekule endotela, Willebrandov
faktor, angiogenin i endotelin-1, koji isto povisuju vaskularnu propusnost.
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